Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Soluble HLA in the Aqueous Humour of Uveal Melanoma Is Associated with Unfavourable Tumour Characteristics.

Wierenga APA, Gezgin G, van Beelen E, Eikmans M, Spruyt-Gerritse M, Brouwer NJ, Versluis M, Verdijk RM, van Duinen SG, Marinkovic M, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 18;11(8). pii: E1202. doi: 10.3390/cancers11081202.

2.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

3.

Correlations between ocular biometrics and refractive error: A systematic review and meta-analysis.

Gaurisankar ZS, van Rijn GA, Lima JEE, Ilgenfritz AP, Cheng Y, Haasnoot GW, Luyten GPM, Beenakker JM.

Acta Ophthalmol. 2019 Aug 6. doi: 10.1111/aos.14208. [Epub ahead of print] Review.

PMID:
31386806
4.

Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.

Chau C, van Doorn R, van Poppelen NM, van der Stoep N, Mensenkamp AR, Sijmons RH, van Paassen BW, van den Ouweland AMW, Naus NC, van der Hout AH, Potjer TP, Bleeker FE, Wevers MR, van Hest LP, Jongmans MCJ, Marinkovic M, Bleeker JC, Jager MJ, Luyten GPM, Nielsen M.

Cancers (Basel). 2019 Aug 4;11(8). pii: E1114. doi: 10.3390/cancers11081114.

5.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

6.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

7.

Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution.

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 13;11(7). pii: E979. doi: 10.3390/cancers11070979.

8.

Ischemia Is Related to Tumour Genetics in Uveal Melanoma.

Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1004. doi: 10.3390/cancers11071004.

9.

Pigmentation of conjunctival melanoma recurrences and outcome.

Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1783-1788. doi: 10.1007/s00417-019-04342-x. Epub 2019 May 16.

PMID:
31098751
10.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Wierenga APA, Cao J, Luyten GPM, Jager MJ.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263. Review. No abstract available.

PMID:
30908279
11.

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK.

J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341. doi: 10.1093/jnci/djy171. Review.

PMID:
30517737
12.

Conjunctival Metastasis of a Cutaneous Melanoma.

Brouwer NJ, Marinkovic M, Jochems A, Kapiteijn EW, van Duinen SG, Haeseker BI, Jager MJ, Luyten GPM.

Ocul Oncol Pathol. 2018 Sep;4(2):107-111. doi: 10.1159/000479114. Epub 2017 Sep 1.

13.

Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients.

van Beek JGM, Buitendijk GHS, Timman R, Muller K, Luyten GPM, Paridaens D, Naus NC, Kiliç E.

Acta Ophthalmol. 2018 Dec;96(8):841-848. doi: 10.1111/aos.13823. Epub 2018 Oct 3.

PMID:
30284368
14.

Lack of tumour pigmentation in conjunctival melanoma is associated with light iris colour and worse prognosis.

Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.

Br J Ophthalmol. 2019 Mar;103(3):332-337. doi: 10.1136/bjophthalmol-2018-312018. Epub 2018 May 18.

PMID:
29777046
15.

Pimasertib-associated ophthalmological adverse events.

van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF.

Acta Ophthalmol. 2018 Nov;96(7):712-718. doi: 10.1111/aos.13677. Epub 2018 Jan 16.

PMID:
29338133
16.

Treatment of conjunctival melanoma in a Dutch referral centre.

Brouwer NJ, Marinkovic M, van Duinen SG, Bleeker JC, Jager MJ, Luyten GPM.

Br J Ophthalmol. 2018 Sep;102(9):1277-1282. doi: 10.1136/bjophthalmol-2017-311082. Epub 2017 Nov 9.

PMID:
29122819
17.

Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal Melanoma.

Brouwer NJ, Luyten GPM, van Duinen SG, Jager MJ, Marinkovic M.

Ocul Oncol Pathol. 2017 Jul;3(2):113-116. doi: 10.1159/000452447. Epub 2016 Nov 9.

18.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

19.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

20.

The Prognostic Value of AJCC Staging in Uveal Melanoma Is Enhanced by Adding Chromosome 3 and 8q Status.

Dogrusöz M, Bagger M, van Duinen SG, Kroes WG, Ruivenkamp CA, Böhringer S, Andersen KK, Luyten GP, Kiilgaard JF, Jager MJ.

Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):833-842. doi: 10.1167/iovs.16-20212.

PMID:
28159971

Supplemental Content

Loading ...
Support Center